Arlington-backed AVS Bio acquires Biorbyt, adding reagents and ecommerce capabilities
Biorbyt, a Cambridge, UK supplier of antibodies, proteins and research reagents with over 1 million SKUs, joins Arlington-backed AVS Bio.
AVS Bio, a Norwich, Connecticut provider of inputs and services for bioprocessing and biologics, said it has acquired Biorbyt Ltd. Biorbyt supplies bio-reagents, antibodies, proteins and other biomaterials for life science research.
Biorbyt's catalog covers more than 1 million SKUs, including primary and secondary antibodies, recombinant and native proteins, ELISA kits, small molecules and molecular biology reagents. It sells through an ecommerce platform to pharma, biotech and academic customers globally.
AVS Bio is a portfolio company of Arlington Capital Partners. Biorbyt will keep its existing leadership and operate as part of the AVS Bio platform. AVS Bio CEO Jac Price said the deal expands its diversified biomaterials offering and global reach.
Deal facts
- Target
- Biorbyt
- Business
- Global supplier of bio-reagents, antibodies, proteins and other biomaterials for life science research, sold through an ecommerce platform
- Acquirer
- AVS Bio
- Backed by
- Arlington Capital Partners
- Deal type
- Add-on
- Headquarters
- Cambridge, UK
- Status
- Completed
- Announced
- Wednesday, September 23, 2026
Sources
- Business WireSep 23, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.